Nutriband Inc. NTRB Archives - Page 2 of 3

FridayMay 09, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Nutriband’s AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch Recent FDA regulatory changes underscore the urgent need for safer opioid delivery methods and responsible prescribing Strategic milestones with partner Kindeva and a strengthened global IP portfolio position Nutriband for long-term growth A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid…

WednesdayApr 30, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare

Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards The CEO’s international perspective and expertise were further validated when he was featured in a recent BBC News article Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband’s mission, achievements and plans for the future Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From…

TuesdayApr 22, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M U.S. sales opportunity as first abuse-deterrent opioid patch Strategic sports partnership with Charlotte FC boosts brand visibility and community presence Strengthening IP for Long-Term Market Protection Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number…

TuesdayApr 15, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients. AVERSA technology can be incorporated into any transdermal patch. The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch. In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support…

MondayApr 14, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of patients Nutriband recently announced two significant partnerships poised to expand its manufacturing capabilities and market reach These partnerships, along with the company’s already existing alliances, align with Nutriband's core mission of developing transdermal pharmaceutical products Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on…

FridayApr 11, 2025 8:50 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5. This adds to Nutriband’s global IP portfolio, with coverage now spanning 46 countries and both SARs of China. AVERSA is designed to reduce abuse, diversion and accidental exposure of transdermal drugs like opioids. Nutriband is advancing development of AVERSA Fentanyl with partner Kindeva Drug Delivery, aiming to commercialize the world’s first abuse-deterrent fentanyl patch…

TuesdaySep 24, 2024 10:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/PeqGN About Nutriband Inc.…

FridaySep 20, 2024 12:45 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

TuesdaySep 17, 2024 8:55 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress on the development of AVERSA Fentanyl, with a target date of submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2025. To view the full press release, visit https://ibn.fm/aLx8t About Nutriband Inc. Nutriband is primarily…

MondayJul 15, 2024 11:15 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes. Nutriband's proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is…

Site Search

Company Search

Tag: Nutriband Inc. NTRB